Dr. Ellis on Neoadjuvant Endocrine Therapy for Breast Cancer

Matthew J. Ellis, MD, PhD
Published: Sunday, May 28, 2017


Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Patients often present with a larger breast mass, which puts the patient at high-risk of systemic recurrence, explains Ellis.

There was a subset of patients who did not see positive results with neoadjuvant chemotherapy, allowing neoadjuvant endocrine therapy to be investigated to attempt to shrink the tumor.
 
SELECTED
LANGUAGE

Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Patients often present with a larger breast mass, which puts the patient at high-risk of systemic recurrence, explains Ellis.

There was a subset of patients who did not see positive results with neoadjuvant chemotherapy, allowing neoadjuvant endocrine therapy to be investigated to attempt to shrink the tumor.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x